MDP
vs
S&P TSX Composite Index (Canada)

Over the past 12 months, MDP has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of 91% compared to the S&P TSX Composite Index (Canada)'s 23% growth.
Stocks Performance
MDP vs S&P TSX Composite Index (Canada)
Performance Gap
MDP vs S&P TSX Composite Index (Canada)
Performance By Year
MDP vs S&P TSX Composite Index (Canada)
Medexus Pharmaceuticals Inc
Glance View
Medexus Pharmaceuticals, Inc. operates as a pharmaceutical company, which provides healthcare products to Healthcare Professionals and patients and focuses on therapeutic areas of auto-immune disease and pediatrics. The company is headquartered in Bolton, Ontario and currently employs 79 full-time employees. The company went IPO on 2012-03-03. The firm is a North American focused, specialty pharmaceutical business that operates through two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada, a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. Medexus Pharma USA, a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States (U.S). The firm is focused on the therapeutic areas of auto-immune disease, hematology, pediatrics, dermatology and allergy. The firm's products are Rasuvo and Metoject, a formulation of methotrexate (auto-pen and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases. The company also offers IXINITY, a medicine for use in patients 12 years of age or older with Hemophilia B and Rupall, an allergy medication.
